Mediterranean diet, Metabolites, and Cardiovascular Disease

地中海饮食、代谢物和心血管疾病

• 批准号: 10551729
• 负责人: Frank B Hu
• 金额: $ 53.38万
• 依托单位: HARVARD SCHOOL OF PUBLIC HEALTH
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-07-15 至 2026-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10551729
• 关键词: Acute myocardial infarction; Adherence; Biological Markers; Body Fluids; Cardiovascular Diseases; Cardiovascular system; Cessation of life; Chickens; Chronic Disease; Complement; Consumption; Data; Data Analytics; Data Reporting; Diet; Dietary Assessment; Dietary Intervention; Dietary Practices; Dietary intake; Disease Outcome; Event; Fabaceae; Fasting; Fishes; Food; Food Patterns; Future; Goals; Grant; Heart failure; Individual; Intake; Intervention; Intervention Trial; Knowledge; Liquid substance; Measurement; Measures; Mediating; Mediterranean Diet; Metabolic; Myocardial Infarction; Nutrition Policy; Nutritional; Nutritional Study; Nuts; Olive oil preparation; Paper; Participant; Pathway interactions; Patient Self-Report; Pattern; Plasma; Prevention; Primary Prevention; Productivity; Publishing; Randomized; Recommendation; Research; Resources; Risk; Role; Sampling; Spottings; Strategic Planning; Stroke; Techniques; Technology; Testing; United States National Institutes of Health; Urine; Work; cardiovascular disorder epidemiology; cardiovascular disorder prevention; cardiovascular disorder risk; cohort; design; dietary; dietary control; evidence base; fruits and vegetables; improved; metabolome; metabolomics; multidimensional data; multidisciplinary; novel; population based; post intervention; precision nutrition; predictive marker; red wine; research vision; response; risk prediction; tool; urinary

ABSTRACT Metabolomics technique holds promise for better understanding the role of diet in cardiovascular disease (CVD) epidemiology and prevention. In particular, a multi-fluid multi-metabolite approach combining urinary and plasma metabolomics will likely enhance the accuracy and precision of nutritional biomarkers, with strong potential to develop novel tools for dietary assessment in precision nutrition research. This competing renewal is aimed to examine the effects of the randomized Mediterranean diet (MedDiet) interventions on urinary metabolite levels and to assess dietary biomarkers' predictive ability for future CVD risk in the landmark PREDIMED trial. We will assess urinary metabolomics in relation to CVD through a case-cohort design, including a representative subcohort randomly sampled from all PREDIMED participants (10%, n=779), and incident CVD cases (including myocardial infarction (MI), stroke, heart failure, and cardiovascular deaths) through December 2017 (n=529). The proposed Specific Aims are: (1) To identify specific urinary metabolites and multi-metabolite signatures of the MedDiet pattern and its main food components; (2) To examine the effects of the randomized dietary interventions on changes in the urinary multi-metabolite signatures of the MedDiet pattern and its major food components from baseline to year 1 (post intervention); (3) To investigate whether baseline and 1-year changes in urinary multi-metabolite signatures of the MedDiet pattern and of individual foods are associated with subsequent risk of CVD; and (4) To develop a multi-fluid (urine and plasma) multi-metabolite signature that robustly predicts risk of CVD and assess whether 1-year changes in the signature mediate the effects of the dietary interventions on the composite CVD outcome. As a sub-aim, we will compare the predictive roles of plasma and urinary metabolites of the MedDiet pattern on CVD risk. This ongoing grant started in 2013 and was renewed in 2017. To date, 36 papers have been published or submitted (including 20 papers in the current grant cycle). The PREDIMED metabolomics data have been used as a resource for replicating metabolomics analyses of CVD outcomes in several US cohorts. This competing renewal application will extend our long-standing research on MedDiet and CVD to multi-fluid multi- metabolite profiling in a large randomized intervention trial. This project leverages numerous strengths of the PREDIMED trial, a multi-disciplinary and highly productive team, cutting-edge metabolomics technologies, and high-dimensional data analytics. The identified dietary biomarkers will enhance the quality and rigor of nutrition research and strengthen the evidence base for developing dietary recommendations and nutrition policies. The proposed work will facilitate the precision nutrition research agenda outlined in the 2020-2030 Strategic Plan for NIH Nutrition Research.

抽象的 代谢组学技术有望更好地了解饮食在心血管疾病 (CVD) 中的作用 流行病学和预防。特别是，结合尿和代谢物的多流体多代谢方法 血浆代谢组学可能会提高营养生物标志物的准确性和精密度，具有强大的作用 在精准营养研究中开发膳食评估新工具的潜力。此次竞相更新 旨在检查随机地中海饮食 (MedDiet) 干预措施对泌尿系统的影响 代谢水平并评估膳食生物标志物对未来心血管疾病风险的预测能力 PREDIMED 试验。我们将通过病例队列设计评估与 CVD 相关的尿液代谢组学， 包括从所有 PREDIMED 参与者中随机抽样的代表性子队列（10%，n=779），以及 CVD 事件（包括心肌梗死 (MI)、中风、心力衰竭和心血管死亡） 截至 2017 年 12 月（n=529）。拟议的具体目标是： (1) 确定特定的尿液代谢物 以及 MedDiet 模式及其主要食物成分的多代谢特征； (2) 检查 随机饮食干预对尿多代谢特征变化的影响 从基线到第一年（干预后）的医疗饮食模式及其主要食物成分； (3) 调查 MedDiet 模式和尿多代谢特征的基线和 1 年变化是否 个别食物与随后的 CVD 风险相关； (4) 开发多流体（尿液和 血浆）多代谢特征，可稳健预测 CVD 风险并评估 1 年变化是否 该特征介导了饮食干预对复合 CVD 结果的影响。作为一个子目标，我们 将比较 MedDiet 模式的血浆和尿液代谢物对 CVD 风险的预测作用。这 持续资助于 2013 年开始，并于 2017 年续签。迄今为止，已发表或发表了 36 篇论文 已提交（包括当前资助周期中的 20 篇论文）。 PREDIMED 代谢组学数据已 用作在美国多个队列中复制 CVD 结果的代谢组学分析的资源。这 竞争性更新应用将把我们对 MedDiet 和 CVD 的长期研究扩展到多流体多 大型随机干预试验中的代谢物分析。该项目充分利用了众多优势 PREDIMED 试验、多学科、高生产力的团队、尖端的代谢组学技术，以及 高维数据分析。确定的饮食生物标志物将提高饮食的质量和严谨性 营养研究并加强制定饮食建议和营养的证据基础 政策。拟议的工作将促进 2020-2030 年精准营养研究议程 NIH 营养研究战略计划。